Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.
Dextromethorphan was granted FDA approval before 3 December 1957.
Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicated in the treatment of pseudobulbar affect.
Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Volunteer recruitment center Covance Leeds Covance Leeds, Leeds, United Kingdom
Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, United States
IPGMER, Kolkata, West Bengal, India
Deptt of Endocrinology, Chandigarh, India
Johns Hopkins Department of Psychiatry, Baltimore, Maryland, United States
HUG, Geneva, Switzerland
Yale-New Haven Hospital St Raphael, New Haven, Connecticut, United States
University of Illinois at Chicago, Chicago, Illinois, United States
Phil Smith Neuroscience Institute at Holy Cross Hospital, Fort Lauderdale, Florida, United States
University of Florida, Gainesville, Florida, United States
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
UC Irvine Health, Orange, California, United States
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.